Business ❯ Pharmaceuticals

Acquisitions

Drug Development Mergers and Acquisitions Sanofi Novartis Biotechnology Merck Corporate Strategy Bristol Myers Squibb Market Trends Pfizer

Novartis Strikes $2 Billion Deal for Mutant-Selective PI3Kα Cancer Drug SNV4818

The Phase 1/2 asset targets PIK3CA‑mutant tumors to improve tolerability in HR+/HER2‑ breast cancer with closing expected in the first half of 2026.

GSK to Acquire Rapt Therapeutics for $2.2 Billion to Add Anti‑IgE Food‑Allergy Drug

Eli Lilly to Acquire Ventyx Biosciences for $1.2 Billion in Bet on Oral NLRP3 Drugs

Mirum to Acquire Bluejay Therapeutics in Up to $820 Million Deal for Hepatitis D Drug

Pfizer’s mRNA Flu Shot Tops Standard Vaccine in Large Phase 3 Trial

Johnson & Johnson to Buy Halda Therapeutics for $3.05 Billion to Bolster Oncology Pipeline

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

Pfizer Closes Metsera Buyout, Adding GLP-1 Assets in Cash-Plus-CVR Deal

Pfizer Clinches $10 Billion Metsera Deal After Novo Nordisk Withdraws

Pfizer Wins Metsera With $10 Billion Cash‑Plus‑CVR Offer as Novo Withdraws

Pfizer Sues to Block Novo Nordisk’s Higher Metsera Bid as Board Backs Revised Offer

Pfizer Sues Metsera and Novo Nordisk to Enforce Deal After Novo’s Higher Bid

Pfizer Wins Early U.S. Antitrust Clearance for Metsera Deal as Novo’s Higher Bid Pressures Timeline

Novartis to Buy Avidity Biosciences for $12 Billion, Adding Muscle-Targeted RNA Drugs

Alkermes to Buy Avadel in Up to $2.1 Billion Deal With CVR Tied to Lumryz Expansion

German Antitrust Watchdog Clears BioNTech’s CureVac Takeover

Bristol Myers Squibb Buys Orbital Therapeutics for $1.5 Billion to Push In Vivo CAR‑T Into Autoimmune Care

Novo Nordisk to Acquire Akero for Up to $5.2 Billion to Expand in MASH

Roemmers Acquires Sidus, Ending 85 Years of Family Control

Genmab Launches $8 Billion Bid for Utrecht Biotech Merus